Portage Biotech (PRTG) Competitors

Portage Biotech (NASDAQ:PRTG) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.

Does the MarketBeat Community prefer PRTG or COEP?

Portage Biotech received 8 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Coeptis Therapeutics an outperform vote while only 59.09% of users gave Portage Biotech an outperform vote.

Company	Underperform	Outperform
Portage Biotech	Outperform Votes 13 59.09%	Underperform Votes 9 40.91%
Coeptis Therapeutics	Outperform Votes 5 83.33%	Underperform Votes 1 16.67%

Is PRTG or COEP more profitable?

Portage Biotech's return on equity of -342.34% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	-342.34%	-196.47%
Coeptis Therapeutics	N/A	-1,094.50%	-219.97%

Do insiders & institutionals believe in PRTG or COEP?

13.4% of Portage Biotech shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 42.1% of Portage Biotech shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable valuation and earnings, PRTG or COEP?

Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	N/A	N/A	-$75.34M	-$41.65	-0.28
Coeptis Therapeutics	N/A	N/A	-$21.27M	-$5.80	-1.45

Which has more risk & volatility, PRTG or COEP?

Portage Biotech has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.68, suggesting that its share price is 168% less volatile than the S&P 500.

Do analysts rate PRTG or COEP?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Coeptis Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media prefer PRTG or COEP?

In the previous week, Coeptis Therapeutics had 4 more articles in the media than Portage Biotech. MarketBeat recorded 11 mentions for Coeptis Therapeutics and 7 mentions for Portage Biotech. Portage Biotech's average media sentiment score of 0.71 beat Coeptis Therapeutics' score of 0.61 indicating that Portage Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Portage Biotech	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Portage Biotech beats Coeptis Therapeutics on 7 of the 13 factors compared between the two stocks.